Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 9, 2017

Study Completion Date

August 9, 2017

Conditions
Ewing's SarcomaOsteosarcomaAstrocytomaAtypical Teratoid/Rhabdoid TumorEpendymomaGerm Cell TumorGliomaMedulloblastomaRhabdoid TumorRetinoblastomaClear Cell SarcomaRenal Cell CarcinomaWilms TumorHepatoblastomaNeuroblastomaRhabdomyosarcoma
Interventions
DRUG

sirolimus

daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.

Trial Locations (1)

30322

Children's Healthcare of Atlanta, Atlanta

Sponsors
All Listed Sponsors
collaborator

Children's Healthcare of Atlanta

OTHER

lead

Emory University

OTHER

NCT01331135 - Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Biotech Hunter | Biotech Hunter